Can I read Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial on EtoBox?

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial by Eve Rodler; Priyanka Sharma; William E Barlow; Julie R Gralow; Shannon L Puhalla; Carey K Anders; Lori Goldstein; Debu Tripathy; Ursa A Brown-Glaberman; Thu-Tam Huynh; Christopher S Szyarto; Andrew K Godwin; Harsh B Pathak; Elizabeth M Swisher; Marc R Radke; Kirsten M Timms; Danika L Lew; Jieling Miao; Lajos Pusztai; Daniel F Hayes; Gabriel N Hortobagyi is a Medicine article available to read on EtoBox.

What is Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial about?

Background Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wildtype triple-negative breast cancer are scarce. A large proportion of germline BRCA1/2-wildtype triple-negative breast cancer shows homologous recombination deficiency (HRD), resulting in a BRCA-like phenotype that might render sensitivity to PARP inhibitors. The S1416 trial assessed the efficacy of cisplatin combined with the PARP inhibitor veliparib in three predefined groups of metastatic breast cancer: germline BRCA1/2-mutated, BRCA-like, and non-BRCA-like. Methods S1416 was a randomised, double-blind, placebo-controlled, phase 2 trial conducted at 154 community and academic clinical sites across the USA. Eligible patients aged 18 years or older had metastatic or recurrent triple-negative breast cancer or germline BRCA1/2-associated metastatic or recurrent breast cancer, an Eastern Cooperative Oncology Group performance status of 0–2, and had received up to one line of chemotherapy for metastatic disease. Patients were randomly

Who reads Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial?

Author

Eve Rodler; Priyanka Sharma; William E Barlow; Julie R Gralow; Shannon L Puhalla; Carey K Anders; Lori Goldstein; Debu Tripathy; Ursa A Brown-Glaberman; Thu-Tam Huynh; Christopher S Szyarto; Andrew K Godwin; Harsh B Pathak; Elizabeth M Swisher; Marc R Radke; Kirsten M Timms; Danika L Lew; Jieling Miao; Lajos Pusztai; Daniel F Hayes; Gabriel N Hortobagyi

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)